









Salivary Glands

NRGHN010
Controlled,
Randomized
Phase II
Docetaxel +
Trastuzumab vs
Ado-Trastuzumab
Emtansine in
Recurrent
Metastatic or
Treatment-Naive
Unresectable
HER2-Positive
Salivary Gland
Cancer

PI: Colevas
Sponsor: NRG

KEY

	Pending		Optional Path		Extension Study
	Open for Enrollment		Trial Posting		Immunotherapy
	Observational Study		Enrollment on Hold		